AACR 2018: Cancer cells actively fuel growth and metastasis by reprogramming healthy cells

Roswell Park Comprehensive Cancer Center researchers have identified a potential key player promoting cancer progression through changes in the cell environment that are conducive to metastasis.

AACR 2018: Combination therapy strengthens T cells in melanoma pre-clinical study

A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when given in combination, may enhance the immune system’s ability to kill melanoma tumours deficient in the tumour suppressor gene PTEN.

AACR 2018: TLR9 agonist CMP-001 / pembrolizumab combination shows early efficacy in patients with metastatic melanoma resistant to anti-PD-1

A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab, tested in patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, was well tolerated and had clinical activity according to preliminary data presented from the ongoing phase Ib clinical trial at the AACR Annual Meeting 2018, April 14-18, in Chicago.

UV confusion: Most Australians don’t know when they need sun protection

It’s the sunburnt country, but an astonishing 92 per cent of Australians do not know they need to start protecting themselves from the sun’s harsh rays when the UV level reaches three or above, new Cancer Council research shows.

Cancer in the News

Feature Articles

Australians in the dark about when to put on sunscreen

The latest data from the Cancer Council Australia’s National Sun Protection Survey shows 40 percent of respondents were confused about what weather factors caused sunburn.

Read the full story

Posted in Melanoma In The News, Information, Latest News

It’s as easy as A, B, C: The simple alphabet mole check to identify cancers and keep your skin safe

While many of us have moles and freckles on our skin, fewer among us spend time analysing these moles and paying close attention to how they look and whether they’ve changed.

Read the full story

Posted in Melanoma In The News, Patient Information

Dr. Weber on Side Effects of Dabrafenib/Trametinib in Melanoma

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the side effect profile of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with melanoma.

Read the full story

Posted in Melanoma In The News, OncLive Videos

Selumetinib Fails to Improve Outcomes With Dacarbazine in Uveal Melanoma

The combination of the MEK inhibitor selumetinib with dacarbazine did not offer improved survival outcomes over placebo plus dacarbazine in patients with metastatic uveal melanoma, according to a phase III trial.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories